AR and prostate cancer: Our model predicted several compounds with cell line specific toxicity for these two prostate cancer cell lines, including HIF1A inhibitor CAY-10585, several androgen receptor related compounds (androstanol, testosterone-propionate and formestane) for VCaP, and antibiotics ornidazole and meclocycline for PC3 (Figure 4C, text labeled data points).